Condition (MeSH)
Ureteral Neoplasms
ClinicalTrials.gov lists 79 trials for Ureteral Neoplasms or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 12.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
79 of the 79 trials are tagged with Ureteral Neoplasms itself; the rest are tagged with a narrower condition beneath it.
When did Ureteral Neoplasms trials start? (25)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 9
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 5 |
| 2024 | 5 |
| 2023 | 3 |
| 2022 | 5 |
| 2021 | 6 |
| 2020 | 2 |
| 2019 | 2 |
| 2018 | 6 |
| 2017 | 9 |
Showing 10 of 25 earlier years.
No forecast is made for this condition: it averages 3.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 10 trials still running at the 2026-10-09 snapshot; registered median of 42 months across 40 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Ureteral Neoplasms trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 14 |
| Phase 1/2 | 5 |
| Phase 2 | 32 |
| Phase 3 | 7 |
| Phase 4 | 1 |
| Not applicable | 7 |
| Observational | 13 |
How many Ureteral Neoplasms trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 15 |
| Active, not recruiting | 15 |
| Completed | 32 |
| Suspended | 1 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Ureteral Neoplasms trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 12 |
| Eli Lilly and Company | 5 |
| Astellas Pharma Global Development, Inc. | 2 |
| AEterna Zentaris | 1 |
Which drugs are being tested for Ureteral Neoplasms? (6)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| PEMBROLIZUMAB | 10 |
| Enfortumab Vedotin | 9 |
| Avelumab | 5 |
| NIVOLUMAB | 4 |
| Vinflunine | 4 |
Showing 5 of 6 drugs.
Interventions as named in the registry (9)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Gemcitabine/Gemzar | 12 |
| Cisplatin 1 | 7 |
| or carboplatin | 5 |
| Atezolizumab SC | 3 |
| Positron Emission Tomography (PET) | 2 |
Showing 5 of 9 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Ureteral Neoplasms trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Fatigue | 145 | 9 |
| Hemoglobin decreased | 135 | 1 |
| Platelet count decreased | 90 | 3 |
| Creatinine increased | 75 | 2 |
| Neutrophil count decreased | 70 | 4 |
Showing 5 of 10 adverse events.
Which publications cover Ureteral Neoplasms? (75)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: Summary of the 2025 Update. | European urology | 2025 | Yes |
| Long-Term Outcomes of Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma With UGN-101, a Mitomycin Reverse Thermal Gel. | The Journal of urology | 2025 | Yes |
| Safety and Efficacy of Neoadjuvant Durvalumab Plus Gemcitabine/Cisplatin or Carboplatin in Patients With Operable High-Risk Upper Tract Urothelial Carcinoma: The iNDUCT-GETUG V08 Trial. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2025 | Yes |
| A Phase 2 Study of Tislelizumab as Neoadjuvant Treatment of Cisplatin-Ineligible High-Risk Upper Tract Urothelial Carcinoma. | The Journal of urology | 2025 | Yes |
| Influence of tumour location on the survival outcomes of upper tract urothelial carcinoma treated with radical nephroureterectomy. | World journal of urology | 2025 | Yes |
Showing 5 of 75 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.